Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

February 23, 2017February 23, 2017

Shorter Course of Radiation Therapy Supported for Prostate Cancer by Oncologists in Editorial

News

Shorter courses of radiation therapy to fight prostate cancer may be just as effective and safe as longer ones, but less costly and burdening to men with the disease, according to ... Read more

February 15, 2017February 15, 2017

Gene Therapy Could Thwart Prostate Cancer Tumor-suppression Mutations, Study Reports

News

Prostate cancer patients who have mutations in the tumor suppressor gene PTEN could benefit from therapies targeting the CHD1 gene, according to a study. The research, “Synthetic Essentiality Of Chromatin ... Read more

February 6, 2017

Protein-blocking Molecule May Increase Risk of Prostate Cancer Spreading, Study Says

News

The small non-coding molecule miR-194 may promote the spread of prostate cancer by blocking the anticancer protein SOCS2, a study says. The finding provides new insight into the molecular mechanisms ... Read more

February 3, 2017February 3, 2017

Imaging Agent Able to Detect Early and Advanced Prostate Cancers by Tracking Biomarkers

News

A new imaging agent may hold promise in detecting both early prostate cancer and metastasis using PET/CT scans, according to data from a first-in-human trial. The agent, a radiolabeled dual-receptor, was ... Read more

January 31, 2017

Androgen Deprivation Therapy Not Found to Increase Risk of Dementia, Alzheimer’s

News

Prostate cancer patients receiving androgen deprivation therapy (ADT) are not at increased risk of dementia or Alzheimer’s disease, according to a study in the Journal of Clinical Oncology. ADT involves ... Read more

January 23, 2017

Telix and Atlab Working to Develop Antibody for Radioimmunotherapy in Advanced Cancers

News

Telix Pharmaceuticals and Atlab Pharma are working together to develop and possibly market huJ591, a monoclonal antibody to be used in radioimmunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). ... Read more

January 4, 2017January 4, 2017

Molecular Pathway That Promotes Aggressive Prostate Cancer Identified in Study

News

A molecular pathway that promotes prostate cancer growth and resistance to anti-cancer therapy was identified in a new study. This finding could help design therapies targeting the molecular components of this pathway, which ... Read more

December 19, 2016December 19, 2016

Xtandi Combo Fails to Improve Survival in Advanced Prostate Cancer Patients in Phase 4 Study

News

Pfizer and Astellas Pharma announced that a Phase 4 clinical trial, investigating longer-term use of Xtandi (enzalutamide) as a combination treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), did not reach its primary goal ... Read more

December 5, 2016December 5, 2016

Prostate Radiation Therapy Induces Changes in Penile Bulb, Causing Erectile Dysfunction

News

Erectile dysfunction, one of the consequences of radiation therapy in men undergoing treatment for prostate cancer, may be associated with changes in the volume of the penile bulb (the bottom ... Read more

December 2, 2016

Novel Antibody May Improve Diagnosis and Management of Prostate Cancer

News

Researchers have developed a new imaging method that may improve diagnosis, monitoring, and treatment of prostate cancer, according to a new study published in Science Translational Medicine. The study, “Internalization ... Read more